Literature DB >> 14504072

Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta.

Juan L Garcia, Jaime Font de Mora, Jesus M Hernandez, Jose A Queizan, Norma C Gutierrez, Jose M Hernandez, Jesus F San Miguel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14504072     DOI： 10.1182/blood-2003-05-1579

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  4 in total

1.  Characteristics and survival of BCR/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database.

Authors:  Smith Giri; Ranjan Pathak; Mike G Martin; Vijaya Raj Bhatt
Journal:  Ther Adv Hematol       Date:  2015-12

2.  Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.

Authors:  Chan Y Cheah; Kate Burbury; Jane F Apperley; Francoise Huguet; Vincenzo Pitini; Martine Gardembas; David M Ross; Donna Forrest; Philippe Genet; Philippe Rousselot; Nigel Patton; Graeme Smith; Cynthia E Dunbar; Sawa Ito; Ricardo C T Aguiar; Olatoyosi Odenike; Alla Gimelfarb; Nicholas C P Cross; John F Seymour
Journal:  Blood       Date:  2014-03-31       Impact factor: 22.113

Review 3.  PDGFRᵝ-Rearranged Myeloid Neoplasm with Marked Eosinophilia in a 37-Year-Old Man; And a Literature Review.

Authors:  Mirela Andrei; Andrei Bandarchuk; Cherif Abdelmalek; Ajay Kundra; Vladimir Gotlieb; Jen Chin Wang
Journal:  Am J Case Rep       Date:  2017-02-17

4.  Myeloid/Lymphoid Neoplasm with PDGFRB Rearrangement with t (5;10) (q33;q22) Harboring a Novel Breakpoint of the CCDC6-PDGFRB Fusion Gene.

Authors:  Miki Yamazaki; Chiaki Nakaseko; Masahiro Takeuchi; Shinichi Ozawa; Yasuhiro Ishizuka; Yasuhito Hatanaka; Nagisa Oshima-Hasegawa; Tomoya Muto; Shokichi Tsukamoto; Shio Mitsukawa; Chikako Ohwada; Yusuke Takeda; Naoya Mimura; Tohru Iseki; Motoharu Fukazawa; Emiko Sakaida
Journal:  Intern Med       Date:  2019-07-22       Impact factor: 1.271
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.